Sign in to view Juan-Pablo’s full profile
or
New to LinkedIn? Join now
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
Sign in to view Juan-Pablo’s full profile
or
New to LinkedIn? Join now
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
San Francisco Bay Area
Sign in to view Juan-Pablo’s full profile
Juan-Pablo can introduce you to 2 people at Action Potential Venture Capital
or
New to LinkedIn? Join now
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
10K followers
500+ connections
Sign in to view Juan-Pablo’s full profile
or
New to LinkedIn? Join now
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
View mutual connections with Juan-Pablo
Juan-Pablo can introduce you to 2 people at Action Potential Venture Capital
or
New to LinkedIn? Join now
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
View mutual connections with Juan-Pablo
or
New to LinkedIn? Join now
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
Sign in to view Juan-Pablo’s full profile
or
New to LinkedIn? Join now
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
About
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
Activity
10K followers
-
Juan-Pablo Mas reposted thisJuan-Pablo Mas reposted thisWhen we launched the PLL, my primary focus was on establishing the pro-league--> creating the best product for fans, attracting top players, and growing the sport from the top down. I still hold that vision close. However, I've come to realize that the PLL Leagues have become just as significant and something I take immense pride in. We created these leagues because we believe that more kids deserve the opportunity to play lacrosse affordably, not just in traditional hotbeds, but across all communities. The response has been incredibly humbling. We've seen communities come together, with kids who had never touched a stick now playing in official PLL gear, meeting professional players, and competing in the Olympic format of our sport. It's real, and it's expanding. I want to emphasize that we didn't achieve this alone; the Coaches are co-builders in this journey. Every successful PLL league has someone at its heart who genuinely loves the game and the kids playing it. These are the individuals who manage field logistics, engage with parents, and dedicate extra time to help struggling players. That person is not us; it's the Coach. We deeply appreciate the coaching community that has trusted us to build something meaningful together. As we look to grow, we want more dedicated Coaches to run Leagues in their communities. There are no franchise or hidden fees. We provide everything necessary: scheduling and registration infrastructure, the PLL brand support, and the resources to make it work. If this resonates with you or someone you know, I would love to connect. A big shoutout to the team that has been building this for the last two years: Jesse Cox, Scott Hillier, Ashley Gersuk Murphy, Kevin Leveille, Eric Witmer, Allan Rabil, Maddie Davis, Devin Townsend Sid Thompson Troy Reh Link in my comment below. 👇
-
Juan-Pablo Mas shared thisOn #WomensDay, I reflect on someone who shaped my understanding of education and leadership long before I understood their importance. My mother, Dr. Vanessa Rivera, spent her career expanding access to engineering and showing us the value of setting our sights high, and working tirelessly. At the University of Massachusetts Amherst, she served as Assistant Dean for Student Affairs in the College of Engineering, overseeing the Women in Engineering and Minority Engineering programs. She helped guide thousands of students through one of the most demanding academic paths — including my brother Gabriel Mas and me. Her impact extended further, as she supported national efforts to expand opportunities for engineers by later leading programs at The University of California, Berkeley and San José State University. Growing up, I remember, after helping me with my homework, her typing late into the night on an Apple IIe finishing her dissertation for a PhD in Education. She even had side hustles like selling Mary Kay Global cosmetics to help pay the bills. Not to mention the countless students she invited into our home for a meal. Almost every one of them would pull me aside and say the same thing: “Your mother is amazing.” She is an accomplished Puerto Rican woman, and single mom (for 9yrs). To this day, she believes deeply that education can change the trajectory of a life. Engineering schools shape the people who go on to build the technologies and companies that define the future. My mom spent her career helping shape those engineers. Now, as I lead the team at Action Potential Venture Capital where we back founders of all types who push the frontier of technology in healthcare and medicine, I continue to draw inspiration from her example and commitment to lifting engineers & scientists up to reach new heights. Love you, Mami 🇵🇷 IEEE Women in Engineering The National GEM Consortium SomosVC All Raise Vanessa Rivera vanessa m. rivera
-
Juan-Pablo Mas shared thisIf you're in Alabama or considering building there, work with Jared on this - trust me.Juan-Pablo Mas shared thisWe're excited for the upcoming 4th cohort of the Overton Fellowship. The deadline to apply is February 13th. The Overton Fellowship is a one-of-a-kind leadership program for entrepreneurs, founders, and changemakers in Birmingham. It's designed for those who want to take their game to the next level. Crafted with a unique combination of coaching, curriculum, connections, and conversations with national leaders, it's an unmatched experience of targeted support and tight-knit community for people changing our city for the better. Alumni consistently say that it's the most effective and transformative professional development opportunity they've ever done. If you’re looking for an experience that will help you reach your next level, this is it. The application takes 20 minutes. Learn more and apply here by Friday, February 13th: https://lnkd.in/dU-PFYCW Birmingham grows when its leaders do. Check out these past Fellows for inspiration — our 2025 cohort: J. W. Carpenter, Merrilee Challiss, Jessica Chriesman, Cori Fain-Forrest, Kevin Ferguson II, Ronnie Gatrey, Brittney Gray, cMf, Xuan Huang, Gaines Johnson, Trent Kocurek, Jessica Majno, Dave Masom, Hannah Mills, Ruth Ann Moss, Tyden Rickard, Austin Senseman; 2024 cohort: Will Blackburn, Delphine Carter, Jarrod Glasgow, Alie B. G., Kara Halfaker, AFC, Garrett Harper, Shekinah Joy Lee MEd,LPC,NCC, Gina McClanahan, Will McGarity, Rachel Morgan, Elliott Potter, James Sutton, Samantha Williams; and 2023 cohort: Erika Boeing, Courtney Davis, Alex Flachsbart, Ace Graham, Emily Jerkins Hall, CEcD, Jahman Hill, Dr. Tamika Holmes, MBA, MHRM, EdD, Emile Hughes, Amelia Muller, AICP, Priska Neely, Troy Whetstone.
-
Juan-Pablo Mas shared thisRecommending this role at OpenAI for the tenacious individual with enterprise software sales experience, focused on life science and healthcare organizations.
-
Juan-Pablo Mas shared thisCongrats to all the investigators and innovators involved. SetPoint Medical #NatureMedicineJuan-Pablo Mas shared this🎉 Thrilled to share exciting news! 🎉 I’m delighted to celebrate the publication of a pivotal study in Nature Medicine titled “Vagus nerve-mediated neuroimmune modulation for rheumatoid arthritis: a pivotal randomized controlled trial” — a major milestone in advancing novel treatment strategies for rheumatoid arthritis (RA). In this randomized, sham-controlled trial of 242 patients with RA who had an inadequate response or intolerance to existing biologic/targeted therapies, targeted vagus nerve stimulation achieved its primary efficacy endpoint at 3 months and demonstrated durable clinical benefits through 12 months, with a favorable safety profile. 💫I’m proud to have contributed to this work as one of the multicenter site Principal Investigators & coauthor collaborating with an outstanding team to help advance a novel, non-pharmacologic neuroimmune therapeutic approach for patients with difficult-to-treat RA. ✨ Why this matters This study highlights the potential of neuroimmune modulation—engaging the inflammatory reflex via vagus nerve stimulation—to expand the therapeutic landscape beyond traditional immunosuppressive strategies and open new pathways for precision, mechanism-based care. 📌 Key takeaways: 💥The trial achieved a statistically significant improvement in ACR20 responses compared with sham stimulation. 💥Clinical improvements continued and strengthened throughout 12 months of open-label stimulation. 💥The therapy was well tolerated with a safety profile comparable to sham. This represents a novel mechanistic approach beyond conventional pharmacologic immunomodulation — expanding the therapeutic landscape for patients with challenging disease. Read the full study here✅️ https://lnkd.in/edCn4gBg Huge congratulations to the authors, collaborators, and participants whose work made this breakthrough possible. Excited to see this move forward into clinical practice and further innovation in immune-mediated disease! 🙌 #RheumatoidArthritis #Immunology #Neuroimmunology #ClinicalResearch #NatureMedicine #InnovationInMedicine SetPoint Medical Kevin J. Tracey #rheumatology #Neurosurgery #VagusNerveStimulation #innovation #medtech Mark RichardsonVagus nerve-mediated neuroimmune modulation for rheumatoid arthritis: a pivotal randomized controlled trial - Nature MedicineVagus nerve-mediated neuroimmune modulation for rheumatoid arthritis: a pivotal randomized controlled trial - Nature Medicine
-
Juan-Pablo Mas shared thisCongrats Simeon and the SR One Capital Management team!Juan-Pablo Mas shared this2025 delivered real outcomes for SR One Capital Management: 🔹$1.9B in pharma upfronts generated by five portfolio companies this year 🔹The largest discovery / platform research deal of 2025 by upfront (ADARx Pharmaceuticals Inc.–AbbVie) 🔹Two private M&A outcomes in under 18 months from initial investment (Renalys Pharma–Chugai Pharmaceutical Co., Ltd. and Elektrofi–Halozyme, Inc.) 🔹Public companies compounding value through execution, not sentiment (Zenas BioPharma, Mineralys Therapeutics, Inc.) This past September also marked five years since SR One spun out from GSK to become an independent investment firm. These outcomes reflect something we have been engineering since 2020: the biotech business model is changing. The prior era was defined by lower costs of capital, longer timelines, and IPO-led liquidity. That model no longer produces durable returns. The next era will reward: 🔹Capital efficiency and faster paths to proof 🔹Early pharma engagement as validation and liquidity 🔹Selective use of public markets to compound and realize value — not to replace private-stage outcomes We built SR One for this moment. Increasingly, this means designing companies and development plans that are global from day one — leveraging transnational execution to compress timelines, reducing capital intensity, and reaching decision-quality data faster. This perspective also shaped how we convened the ecosystem. At the SR One Summit this fall, we brought together portfolio executives, pharma leaders, and LPs for direct conversations about what it takes to build, scale, and exit biotech companies in this cycle. The conclusion was clear: judgment, partnership, and execution now matter more than ever. If the last decade of biotech rewarded capital abundance, the next will reward precision — in science, capital allocation, and collaboration. 2025 showed what that looks like in practice. Let’s keep building.
-
Juan-Pablo Mas reposted thisJuan-Pablo Mas reposted this2025 marked a significant year of growth and impact for Pacific Northwest Native Lacrosse I am deeply grateful to Creator and to the many Tribal communities, families, partners, and supporters who made this work possible. In 2025, PNW Native Lacrosse served 700+ Native youth through 42 camps and clinics, including our first professional camp in partnership with Jake Piseno and PLL Assists. We fielded 7 All-Native teams across 3 major tournaments, hosted our first-ever All-Native multi-team tournament, launched our first Girls team, delivered 2 girls-specific camps, gifted 200+ lacrosse sticks, and participated in 10 speaking engagements to educate audiences about the Indigenous origins of the game. This year also marked a significant milestone as PNW Native Lacrosse became a 501(c)(3) nonprofit organization. This allowed us to provide camps, clinics, and travel-team programming at no cost to families beyond travel costs, further removing financial barriers and increasing access to the Creator’s Game. Our impact extended well beyond competition. PNW Native Lacrosse was featured by the Premier Lacrosse League on ESPN, KING 5 Evening Magazine, and Oregon Public Radio. We launched Respect the Roots, which was adopted by the Premier Lacrosse League; delivered Land and Game Acknowledgements at major lacrosse events, including the WLL All-Star Game; contributed to Indigenous Peoples Day storytelling; and I was honored to be appointed to the USA Lacrosse Native American Advisory Council. Throughout the year, our team traveled thousands of miles across Washington, Utah, Arizona, Oregon, California, Kansas, Minnesota, and Canada, strengthening relationships, creating access, and reclaiming space for Native youth in the Creator’s Game. I am deeply proud of our players, families, coaches, and partners who carried this work forward with humility, care, and purpose. We look ahead to 2026 with continued focus on access, cultural grounding, and long-term impact. Lacrosse is a Native Game played on Native Land.
-
Juan-Pablo Mas reposted thisEverything we do is privately funded. We DO NOT receive any government funding. We positively impact more kids and athletes in lacrosse at scale across the U.S. than any other organization on the planet. All from donations, membership, and sponsor partners. If you believe the impact lacrosse and/or youth sports had on you, your family, friends, and community - please give. United States Olympic & Paralympic Committee, LA28 Olympic & Paralympic Games, #youthsportsJuan-Pablo Mas reposted thisWith $28, you can equip a new player and grow the future of lacrosse. Make your #GivingTuesday impact.
-
Juan-Pablo Mas reposted thisJuan-Pablo Mas reposted this🔥 Tomorrow's the day! There's still time to join us for the SomosVC Annual Summit 2025 in San Francisco! I'm especially excited to be moderating this year's LP panel: Staying Power - Lessons from LPs Who’ve Backed the Best. Featuring: • Katie Duval (Kelly), Top Tier Capital Partners • Jessie Jia Guo, Next Legacy • Kimberli Cavazos Haywood, Candide Group These LPs have backed some of the strongest managers in the industry and they'll share what truly drives long-term success. For emerging managers and those fundraising, you won't want to miss this conversation! 🚀 This year's summit theme, Fuerza y Futuro, reflects both the resilience of our community and the opportunity ahead of us. There's still time to register - join investors, LPs, and founders for an incredible day of insights. Registration link below👇 https://luma.com/hb6r7rbq
-
Juan-Pablo Mas liked thisJuan-Pablo Mas liked thisHappy International Women’s Day. My mother was everything to me. Though she is no longer with my family and me, she taught me to be kind and to be persistent and to be strong in the face of hardship. She taught me that a heart can be as strong as stone yet as soft as water. She taught me the power of grace and of caring and looking out for your people. She taught me that real strength lies in lifting people up and treating everyone with respect and decency - values and principles I strive to embody in my professional journey and that continue to impact and guide me to this day. They also seem to be greatly in need right now. “Men alone are somewhat of a disaster,” a famous & wise president used to say. I couldn’t agree more. There's not a greater force of nature than a strong and noble woman. Period full stop. ;) #IWD
-
Juan-Pablo Mas liked thisJuan-Pablo Mas liked thisHeading to #ISHLT2026? Don’t miss “Barostim: Flipping the Parasympathetic Switch.” Join expert faculty as they discuss how #Barostim complements GDMT to target the neurohormonal mechanisms behind #heartfailure. Drs. Peter Eckman, Shelley Hall, Matthew Danter, and Farooq Sheikh will share perspectives on evidence, patient selection, surgical approach, and building strong multidisciplinary programs. They’ll also explore what’s next, including insights into the emerging BENEFIT-HF trial. Add to calendar: https://barost.im/4t6CHWg
-
Juan-Pablo Mas liked thisJuan-Pablo Mas liked thisGo Starlight Cardiovascular!!! 🫀First patient down and many more to go. So proud of this incredible human Beverly Tang for tackling congenital heart disease ♥️ when she could have had any corporate job she wanted… Our patients and families will be forever grateful for you and your team ⭐️ Impact1 at Stanford Biodesign Stanford Medicine Children's Health Stanford Mussallem Center for Biodesign
-
Juan-Pablo Mas liked thisJuan-Pablo Mas liked thisIt’s been a while since I’ve shared an update here. After many years building and scaling products in consumer health and wellness (Verily, Peloton and most recently Dexcom), I realized it was time to work differently - closer to early-stage building, both supporting founders and building something of my own. In practice, that has taken a few forms: a CPO engagement with a health startup (more on that soon), some early-stage advisory work, and building something new at the intersection of women’s strength training and metabolic health. All different expressions of the same mission that’s driven most of my career: helping people better understand and actively shape their health. It’s been energizing to move quickly again - building, testing ideas, and collaborating with thoughtful people who care deeply about the problems they’re solving. I recently got to talk about this chapter on the ReInvention podcast. Huge thanks to Chris Thide and Todd Jason for having me - and to the broader ReInvention community for creating such a thoughtful space for conversations like this. Podcast link in the comments if you’re curious. If you’re in the Bay Area and passionate about women’s health & fitness, I’d especially love to hear from you. And if you’re building something interesting in health, wellness or consumer tech more broadly - always happy to connect.
-
Juan-Pablo Mas liked thisJuan-Pablo Mas liked thisDxD students were thrilled to visit the Stanford Mussallem Center for Biodesign as part of the 2026 Pathways in Health Technology program. Director and co-founder Josh Makower warmly welcomed students with an overview of the Stanford Mussallem Center for Biodesign. Then students were coached on their group project by Biodesign Fellows Charlene Tang, Emeka John Amamdikwa, Marisa Markovich, Mathias Vissers, MD, César Fuentes-Ortega, Asha Kirchhoff and Justin Penny, MD, MS, MBA. Thank you to all of the fellows and especially Linda Lucian for so generously sharing your time, space and expertise with our aspiring healthtech problem-solvers! Students also met Olivia Stroud and learned about her unique journey from training as a dancer to becoming a medtech product manager for Edwards Lifesciences. Then, in Ingrid Ellerbe's chat with Kavita Bouknight, students learned more about why diversity within the healthtech innovation ecosystem is essential for improving health outcomes for all. Finally, students heard a talk from Ronald Page II, focusing on the importance of developing an empowered mindset -- one that will help them succeed in any career they choose. As we near the end of the 2026 Pathways program, we're excited to see how they put all of these learnings together for their final presentations ... just a week away! #DxDPathways #Innovation #Biodesign #DxDPathways
-
Juan-Pablo Mas liked thisJuan-Pablo Mas liked this“Why should this person be interested in what I’m doing? And if you can’t think of that, then it’s probably not going to be a fit.” — Peter Hebert Now live on our website: LSI USA ‘26 Keynote with Peter Hébert, Co-Founder and Managing Partner of Lux Capital, and Armen Vidian, Co-Founder and Co-Managing Partner of Recode Ventures. Watch the full Keynote here: https://lnkd.in/g6m7_SDr Peter co-founded Lux Capital with the idea that in order to have the biggest impact on the future, one should support the most scientifically and technologically ambitious ventures. Two decades later, Lux has expanded from its New York City roots to Silicon Valley and built a $5+ billion AUM firm of more than 30 full-time professionals, with a wide spectrum of technical backgrounds and the versatility to invest at any stage. Armen has nearly 30 years of experience as an engineer, entrepreneur, and investor in technology and healthcare. In 2022, Armen co-founded Recode Ventures, the world's first specialist venture capital firm dedicated to investing in healthcare AI companies. With his co-Managing Partner, Vishal Gulati, M.D., they focus on pre-seed, seed, and Series A companies at the intersection of AI with healthcare and the life sciences, backing founders who share their belief that AI and other platforms have the potential to revolutionize healthcare and to dramatically accelerate the treatment and cures of diseases that impact all of us. Want to join us at our next event? Registration, presenter applications, sponsorship opportunities, and our special hotel block rates are open for LSI Asia ‘26. Secure your spot today to join us at LSI Asia ‘26 on June 30 - July 2 at the Shangri-La Singapore.Keynote: Peter Hebert, Co-Founder of Lux Capital, and Armen Vidian, Co-Founder of Recode Ventures | LSI USA '26Keynote: Peter Hebert, Co-Founder of Lux Capital, and Armen Vidian, Co-Founder of Recode Ventures | LSI USA '26
-
Juan-Pablo Mas liked thisJuan-Pablo Mas liked thisMorning panels from day 2 of LSI USA ‘26! Medtech M&A: An Optimist’s Perspective on the Future of Medtech • John Heinbigner — EY • Chris Eso — Medtronic • Bennett Blau — Evercore • Greg Banker — Vensana Capital • Chad Rice — Edwards Lifesciences SetPoint Medical: Redefining Bioelectronic Therapy • Roger Brooks — RBrooks Group • Brandon Rice — Piper Sandler • Juan-Pablo Mas — Action Potential Venture Capital • Zack Scott — Norwest Venture Partners • Ankit S. — SetPoint Medical • Josh Makower — Sofinnova Partners, Stanford Mussallem Center for Biodesign Beyond Protocols: AI’s Role in Uncharted Treatment and Patient Outcomes • Kelly Huang, PhD — Elucid • Anne Osdoit — Moon Surgical and Sofinnova Partners • Dinesh Kumar, PhD, MBA — Blend Health • Cody Simmons — DermaSensor Transforming Care Through Global Innovation: Cedars-Sinai and Its International Partners • Julien Brohan — Cedars-Sinai Technology Ventures • Nirdesh K Gupta, PhD — Cedars-Sinai Technology Ventures • Heather Roxborough — Oxford Science Enterprises • Emir Sandhu, MD — Sandbox Industries & The Blue Venture Fund #LSIUSA26
-
Juan-Pablo Mas liked thisJuan-Pablo Mas liked thisHear from our Chief Technology Officer, Dean Karantonis, on what makes the Evoke® System truly different. The Evoke® System responds to the body in real time, delivering consistent therapy so patients can get the relief they need with every heartbeat, breath, and movement. Risks and Important Safety Info https://lnkd.in/g39neeNq Rx Only The Saluda Medical Evoke® System is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs. #EvokeTherapy #ClosedLoopSCS
-
Juan-Pablo Mas liked thisJuan-Pablo Mas liked thisBREAKING: WHOOP RAISES $575M AT $10.1B VALUATION Today marks an important milestone for Whoop. We’ve raised $575M at a $10.1B valuation to accelerate our mission of unlocking human performance and healthspan globally. This round brings together an extraordinary group of investors that reflects both where we’ve come from and where we’re going. It was led by Collaborative Fund with participation from 2PointZero Group, Qatar Investment Authority, Mubadala, Abbott, Mayo Clinic, Macquarie Group, Glade Brook Capital Partners LLC, B-FLEXION, IVP, Foundry, Accomplice, Affinity Partners, Promus Ventures, and Bullhound Capital alongside a group of individual investors including Cristiano Ronaldo, LeBron James, Rory McIlroy, Virgil van Dijk, and Mathieu van der Poel. This investor group and this moment reflect a powerful evolution underway for Whoop and the broader healthcare market. Whoop was born in performance - trusted by the best athletes in the world to train, recover, and compete at the highest level. That foundation remains core to who we are. You see that in the iconic athlete investors joining this round. But it also represents our push into broader health. In the past 12 months, Whoop has received medical clearances, launched blood testing, and created a platform that has saved lives. Abbott and Mayo Clinic - two of the most respected and influential institutions in global healthcare - are now investors in Whoop. These are organizations that have shaped modern medicine. Their decision to partner with us is a clear validation of where our technology is headed. Healthcare systems around the world are reactive. For too long, they have waited for people to get sick, then intervene. Chronic disease is rising and costs continue to climb. At Whoop, we believe the future looks fundamentally different. We are building the most powerful, personal, preventive health platform in the world - powered by continuous biometric data, advanced analytics, and AI to help people understand their bodies and improve their health in real time. I am grateful to our team, our members, and our partners for believing in this vision. I’ve been building this company for 14 years and I’ve never been more excited for the future. Onwards! #WHOOP #financing #growth #health #wearables #hiring
Experience & Education
-
Action Potential Venture Capital
******** ********
-
******* ******** ***
***** ********
-
******** *******
***** ********
-
******** ********** ******** ****** ** ********
*** undefined undefined
-
******** **********
** undefined
View Juan-Pablo’s full experience
See their title, tenure and more.
Welcome back
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
New to LinkedIn? Join now
or
By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.
Recommendations received
1 person has recommended Juan-Pablo
Join now to viewView Juan-Pablo’s full profile
-
See who you know in common
-
Get introduced
-
Contact Juan-Pablo directly
Other similar profiles
Explore more posts
-
Michael J. Cunningham, MBA
8K followers
Med and AI Tech in Focus Smart Bandage Detects Inflammation and Infection Researchers at California Institute of Technology have developed a smart bandage called iCares that continuously monitors fluids in wound sites in real time to assess inflammation and infection. The bandage is equipped with three different microfluidic components. One removes moisture from the wound to help with healing. Another detects nitric oxide and other molecules that indicate wound inflammation. A third component detects hydrogen peroxide, which is another biomarker of infection which occurs one to three days before patients experience symptoms. The iCares bandage was designed for patients with chronic wounds that are slow to heal, because of diabetes or poor blood flow at the wound site. iCares is composed of a flexible strip that can be 3-d printed and incorporates a disposable biomarker sensor array together with reusable circuit board that handles signal processing and wireless data transmission. A machine learning algorithm is used to classify and monitor any changes in patients’ wounds in real-time and can send a signal and data to a Smartphone. VC Investors are always adjusting their "Play Book" with a variety of options for investing. Mikal Ventures is one of those alternatives, offering curated solutions to real world problems. Reach out if you have questions on how we can be of assistance and bookmark https://mikalventures.com/ for additional insights and information.
1
-
Christopher Malter
564 followers
Med and AI Tech in Focus Smart Bandage Detects Inflammation and Infection Researchers at California Institute of Technology have developed a smart bandage called iCares that continuously monitors fluids in wound sites in real time to assess inflammation and infection. The bandage is equipped with three different microfluidic components. One removes moisture from the wound to help with healing. Another detects nitric oxide and other molecules that indicate wound inflammation. A third component detects hydrogen peroxide, which is another biomarker of infection which occurs one to three days before patients experience symptoms. The iCares bandage was designed for patients with chronic wounds that are slow to heal, because of diabetes or poor blood flow at the wound site. iCares is composed of a flexible strip that can be 3-d printed and incorporates a disposable biomarker sensor array together with reusable circuit board that handles signal processing and wireless data transmission. A machine learning algorithm is used to classify and monitor any changes in patients’ wounds in real-time and can send a signal and data to a Smartphone. VC Investors are always adjusting their "Play Book" with a variety of options for investing. Mikal Ventures is one of those alternatives, offering curated solutions to real world problems. Reach out if you have questions on how we can be of assistance and bookmark https://mikalventures.com/ for additional insights and information.
4
-
Giovanni Lauricella
Lifeblood • 36K followers
Israeli MedTech: Restore Medical secures $23M Series B to push forward novel heart failure therapy The new funding will allow the Israeli startup to complete an ongoing feasibility study in Europe, where early results have shown what the company describes as encouraging long-term safety and efficacy data. Amongst the challenges of building a medical device company, fundraising, and global dynamics, it is a blessing to be able to watch Gilad Marom and team continue to succeed with their development! https://lnkd.in/eNjvg2cd
45
2 Comments -
Alice Bentinck
Entrepreneurs First • 15K followers
Check out the latest from Limbic - their breakthrough study in Nature Portfolio, shows how Limbic turns frontier language models into behavioral health specialists. In their pre-registered, double-blind randomized trial they showed that: 1️⃣ Adding the Limbic Layer improves AI-led therapy performance by 43% 2️⃣ Clinicians preferred Limbic over general-purpose LLMs 83% of the time 3️⃣ 74% of Limbic's AI sessions ranked among the top 10% of therapists 4️⃣ Patients rate the Limbic experience as comparable to clinician-led sessions Amazing stuff from Ross Harper and Sebastiaan de Vries - delighted to have them in the Entrepreneurs First portfolio.
49
1 Comment -
Milad Alucozai
Pamir Ventures • 37K followers
I turn down 99% of non-profit board and advisory requests. Digitalis Commons is the 1%. They're not just talking about bridging the digital divide. They're building the infrastructure to actually do it. Their mission: ensuring every American has access to the digital tools and skills that define opportunity in 2025. Not someday. Now. What convinced me to join as Expert in Residence: • Real impact metrics, not vanity statistics • Technology-first approach to scaling solutions • Focus on underserved communities where the need is greatest • Leadership that measures success by lives changed, not dollars raised As someone who's spent years at the intersection of AI, healthcare, and deep tech, I see how the digital divide compounds every other inequality. Healthcare access. Educational opportunity. Economic mobility. They all require digital literacy now. The best non-profits don't ask for your time. They earn it through impact. Digitalis Commons earned mine. To the team: Lara Mangravite, Cierra Crowder-Lopez, Sia Anagnostou, Janice Louie, Justin Levy, Idin Jafari Jack McGee, Sarah Valentine, Geoffrey Smith, Misti Ushio, Brian Trelstad, Jennifer Friel Goldstein, excited to roll up our sleeves and build something that matters. Let's bridge this divide one community at a time. Because serving your country isn't just about what you build in the private sector. It's about ensuring everyone has the tools to build their own future. #DigitalEquity #NonProfit #TechForGood #SocialImpact #CommunityDevelopment
60
4 Comments -
Ken Horenstein
Pack Ventures • 10K followers
Big News at Pack Ventures 🚀🐺🧬 We’re thrilled to welcome two outstanding Venture Partners to the Pack Ventures team! Jenny Cronin, PhD and William Canestaro, PhD are two of the most respected and well-connected figures in the Seattle biotech landscape. They strengthen our mission of building the leading pre-seed biotech fund in Seattle—a city we believe is one of the most important biotech markets in the world for the convergence of A.I. and Biotech! Seattle isn’t just home to world-class institutions like the Institute for Protein Design, University of Washington, Fred Hutch, and Seattle Children's —it’s also a global hub where AI and biotech converge. From David Baker’s recent #NobelPrize to the cutting-edge work coming out of the Paul G. Allen School of Computer Science & Engineering, Microsoft, Amazon, and the Allen Institute and Ai2 , the depth of A.I. talent here is extraordinary. At Pack Ventures, we’re doubling down on the Seattle and UW innovation ecosystem. Our belief is simple: the next generation of industry-defining biotech companies will be built here—and we’re here to help founders make that future a reality. With our new Venture Partners on board, we’re better equipped than ever to support early-stage founders transforming science into scalable solutions. #Biotech #VentureCapital #AIxBio #SeattleInnovation #PackVentures #UWSpinouts #TechBio
369
33 Comments -
Lucas Buchheim-Jurisson
POM Health Systems • 4K followers
Tarek Mouhieddine M.D. and I are excited to announce that POM Health is coming out of stealth today and opening a limited beta to early customers. We were founded with a simple mission of catching as many cancers as possible as early as possible and upgrading a cancer screening paradigm that too often catches disease late. In the U.S., screening catches just ~14% of cancer cases, and around half of diagnoses are made at Stage III+. Despite having world-class detection technologies, we routinely screen for just 5 out of 200+ cancer types, often at multi-year intervals between screens, and most people won’t interact with an oncologist until there’s already a high suspicion of cancer. The result: 625k+ deaths from cancer annually in the US, 70% of which are in cancers without guideline-recommended screening, and far too many people believe their annual physical is an effective warning system. Elite cancer centers around the world (like where Tarek practices) have made significant advances in cancer detection and interception that have not yet translated to our primary care and insurance-driven screening system. With AI, we can now bring these advances to millions. Through POM Health, we offer access to more comprehensive cancer screening. Screening is led by world class oncologists, powered by AI, and accessible via telehealth, with one-time and annual subscription offerings. POM's cancer screens use multiple detection modalities (including sample-based biomarkers, MCED, imaging, and genetics) to provide broad coverage across 90%+ of cancers, with overlapping coverage for 80%+. When a cancer signal is detected, your POM oncologist drives the next step quickly. The lifetime risk of acquiring cancer stands at 39% in the US and early onset cancers have doubled since 1990. Cancer isn't a rare disease and we believe people should have an option to mitigate their cancer risk. Now serving beta test users in: MA, NY, and FL (CA soon, and waitlist open for all other states) Learn more: https://lnkd.in/e9qcaru9 Questions: lucas@pomhealth.xyz or tarek@pomhealth.xyz (POM = Peace of Mind, which everyone deserves when it comes to cancer) Thanks also to our first investor Leo Korsunsky!
42
8 Comments -
Michael Sidler
redalpine • 13K followers
Behind every #FDA clearance is a founder who refused to take *NO* for an answer. 🧬🚀 Last month, two! of our portfolio companies reached major regulatory milestones: Hypervision Surgical received FDA 510(k) clearance for its HYPERSNAP® system - the first surgical platform to combine Hyperspectral Imaging with AI-powered analytics for intraoperative decision support. Hilo by Aktiia secured FDA OTC clearance for the Hilo Band - the world’s first cuffless blood pressure monitor approved for over-the-counter use in the US. No cuff. No prescription. Just clinical-grade blood pressure data from the wrist. And with tackling hypertension they were going after one of the biggest global health challenges. Both breakthroughs reflect what we look for at redalpine: long-term commitment to science, and ambition to reimagine healthcare from first principles. As Josep Solà, co-founder and CTO at Hilo by Aktiia, put it: “𝘖𝘶𝘳 𝘨𝘰𝘢𝘭 𝘸𝘢𝘴 𝘤𝘭𝘦𝘢𝘳 𝘧𝘳𝘰𝘮 𝘵𝘩𝘦 𝘣𝘦𝘨𝘪𝘯𝘯𝘪𝘯𝘨: 𝘵𝘰 𝘤𝘳𝘦𝘢𝘵𝘦 𝘢 𝘱𝘳𝘰𝘥𝘶𝘤𝘵 𝘵𝘩𝘢𝘵 𝘸𝘰𝘶𝘭𝘥 𝘣𝘦 𝘶𝘴𝘦𝘥 𝘢𝘴 𝘪𝘯𝘵𝘶𝘪𝘵𝘪𝘷𝘦𝘭𝘺 𝘢𝘯𝘥 𝘦𝘧𝘧𝘰𝘳𝘵𝘭𝘦𝘴𝘴𝘭𝘺 𝘢𝘴 𝘢 𝘴𝘮𝘢𝘳𝘵𝘱𝘩𝘰𝘯𝘦. 𝘉𝘶𝘵 𝘣𝘦𝘩𝘪𝘯𝘥 𝘵𝘩𝘢𝘵 𝘴𝘪𝘮𝘱𝘭𝘪𝘤𝘪𝘵𝘺, 𝘵𝘩𝘦 𝘥𝘦𝘷𝘪𝘤𝘦 𝘸𝘰𝘶𝘭𝘥 𝘨𝘦𝘯𝘦𝘳𝘢𝘵𝘦 𝘤𝘭𝘪𝘯𝘪𝘤𝘢𝘭𝘭𝘺 𝘢𝘤𝘤𝘶𝘳𝘢𝘵𝘦 𝘣𝘭𝘰𝘰𝘥 𝘱𝘳𝘦𝘴𝘴𝘶𝘳𝘦 𝘥𝘢𝘵𝘢, 𝘧𝘪𝘵 𝘧𝘰𝘳 𝘮𝘦𝘥𝘪𝘤𝘢𝘭 𝘥𝘦𝘤𝘪𝘴𝘪𝘰𝘯-𝘮𝘢𝘬𝘪𝘯𝘨.” That required more than just science. “𝘛𝘩𝘦 𝘵𝘳𝘶𝘦 𝘨𝘢𝘵𝘦𝘬𝘦𝘦𝘱𝘦𝘳 𝘵𝘰 𝘵𝘩𝘢𝘵 𝘷𝘪𝘴𝘪𝘰𝘯? 𝘕𝘰𝘵 𝘫𝘶𝘴𝘵 𝘧𝘶𝘯𝘥𝘪𝘯𝘨. 𝘕𝘰𝘵 𝘫𝘶𝘴𝘵 𝘵𝘦𝘢𝘮. 𝘕𝘰𝘵 𝘦𝘷𝘦𝘯 𝘶𝘴𝘦𝘳 𝘢𝘥𝘰𝘱𝘵𝘪𝘰𝘯. 𝘐𝘵 𝘸𝘢𝘴, 𝘢𝘯𝘥 𝘴𝘵𝘪𝘭𝘭 𝘪𝘴, 𝘳𝘦𝘨𝘶𝘭𝘢𝘵𝘰𝘳𝘺 𝘢𝘱𝘱𝘳𝘰𝘷𝘢𝘭.” Hypervision Surgical’s approach was equally strategic. For CEO and co-founder Michael Ebner, early alignment with the FDA was a key part of their roadmap: “𝘐𝘯𝘪𝘵𝘪𝘢𝘵𝘦 𝘦𝘯𝘨𝘢𝘨𝘦𝘮𝘦𝘯𝘵 𝘸𝘪𝘵𝘩 𝘵𝘩𝘦 𝘍𝘋𝘈 𝘢𝘴 𝘦𝘢𝘳𝘭𝘺 𝘢𝘴 𝘱𝘰𝘴𝘴𝘪𝘣𝘭𝘦 - 𝘪𝘥𝘦𝘢𝘭𝘭𝘺 𝘪𝘯 𝘱𝘢𝘳𝘢𝘭𝘭𝘦𝘭 𝘸𝘪𝘵𝘩 𝘥𝘦𝘷𝘦𝘭𝘰𝘱𝘪𝘯𝘨 𝘢 𝘷𝘪𝘢𝘣𝘭𝘦, 𝘦𝘷𝘰𝘭𝘷𝘪𝘯𝘨 𝘤𝘰𝘮𝘮𝘦𝘳𝘤𝘪𝘢𝘭 𝘴𝘵𝘳𝘢𝘵𝘦𝘨𝘺. 𝘛𝘩𝘢𝘵 𝘦𝘢𝘳𝘭𝘺 𝘥𝘪𝘢𝘭𝘰𝘨𝘶𝘦 𝘩𝘦𝘭𝘱𝘴 𝘳𝘦𝘥𝘶𝘤𝘦 𝘶𝘯𝘤𝘦𝘳𝘵𝘢𝘪𝘯𝘵𝘺 𝘢𝘯𝘥 𝘢𝘤𝘤𝘦𝘭𝘦𝘳𝘢𝘵𝘦𝘴 𝘦𝘷𝘦𝘳𝘺𝘵𝘩𝘪𝘯𝘨 𝘥𝘰𝘸𝘯𝘴𝘵𝘳𝘦𝘢𝘮.” He also encourages founders to explore fast-track pathways: “𝘊𝘰𝘯𝘴𝘪𝘥𝘦𝘳 𝘱𝘳𝘰𝘨𝘳𝘢𝘮𝘴 𝘭𝘪𝘬𝘦 𝘵𝘩𝘦 𝘍𝘋𝘈’𝘴 𝘚𝘛𝘦𝘗 (𝘚𝘢𝘧𝘦𝘳 𝘛𝘦𝘤𝘩𝘯𝘰𝘭𝘰𝘨𝘪𝘦𝘴 𝘗𝘳𝘰𝘨𝘳𝘢𝘮) 𝘰𝘳 𝘉𝘳𝘦𝘢𝘬𝘵𝘩𝘳𝘰𝘶𝘨𝘩 𝘋𝘦𝘷𝘪𝘤𝘦𝘴 𝘋𝘦𝘴𝘪𝘨𝘯𝘢𝘵𝘪𝘰𝘯 (𝘉𝘋𝘋). 𝘛𝘩𝘦𝘴𝘦 𝘦𝘯𝘤𝘰𝘶𝘳𝘢𝘨𝘦 𝘰𝘯𝘨𝘰𝘪𝘯𝘨, 𝘱𝘳𝘰𝘢𝘤𝘵𝘪𝘷𝘦 𝘤𝘰𝘮𝘮𝘶𝘯𝘪𝘤𝘢𝘵𝘪𝘰𝘯 𝘢𝘯𝘥 𝘤𝘢𝘯 𝘩𝘦𝘭𝘱 𝘧𝘢𝘴𝘵-𝘧𝘰𝘳𝘸𝘢𝘳𝘥 𝘵𝘩𝘦 𝘳𝘦𝘨𝘶𝘭𝘢𝘵𝘰𝘳𝘺 𝘵𝘪𝘮𝘦𝘭𝘪𝘯𝘦.” Congratulations to Josep Solà, Michael Ebner, and both incredible teams. This is what #empoweringGameChangers looks like. #FDA #HealthTech #Wearables #Surgery #DigitalHealth #Hypertension #MedicalDevices #VentureCapital #redalpine
141
9 Comments -
Henry O'Connell
Canary Speech • 13K followers
We’re thrilled to be collaborating with Intermountain Health and Dr. West on this groundbreaking initiative. Together, we’re advancing the development of an ambient, non-intrusive vocal assessment solution that leverages Canary Speech’s patented vocal biomarker technology. This work aims to enhance clinical decision support by enabling real-time insights through everyday speech—bringing us closer to a future where voice becomes a powerful window into health and wellness.
28
3 Comments -
Dongxue W.
Diatiro • 4K followers
In the context of MedTech innovation, research often relies on proprietary data from private companies. Can a study using such data truly be "scientific" if the data-generation process and raw data cannot be made public? I think the statement from King, Keohane, and Verba (Princeton University Press, 1994) that research procedures must be "explicit, codified, and public" is profoundly thought-provoking for venture investment in the scientific valuation process in the MedTech sector. While intellectual property (IP) protection and non-disclosure agreements are critical to a startup's secret sauce, they create direct tension with this core principle of scientific inquiry. This tension is at the heart of venture due diligence for any data-driven health innovation. We must evaluate if a company's claims are "scientific enough" to be credible, even when the data itself is a closely guarded secret. The investor's dilemma: trust vs. transparency On one hand, a startup's proprietary data is its most valuable asset. It underpins a unique algorithm, a novel diagnostic tool, or a new therapeutic approach. Demanding full public disclosure of this data would be a non-starter; it would destroy the company's competitive advantage. On the other hand, without transparency, we lose the fundamental mechanisms of scientific validation outlined by King et al.: 1. Replicability; 2. Peer review; 3. Uncertainty assessment This creates a high-stakes information asymmetry where investors and potential partners must take a leap of faith. At today’s research design method session, Professor Stephen Linder, Professor Aanand D. Naik, M.D. , and Professor Stephanie Silveira guided a group of fellow researchers at The University of Texas Health Science Center at Houston (UTHealth Houston) to discuss the research design nuances between qualitative, quantitative, and mixed methods approaches, I brought up this question, and some insightful takeaways and recommendations sound realistic and practical to me. A recommended solution: To resolve this, it is considerable to adopt a modified standard for "scientific" credibility that focuses on what can be made public without compromising the core IP. The diligence process shall be designed to push for maximum transparency on the METHODOLOGY, rather than the raw data itself. This aligns with a comment from Professor Stephen Linder, who noted that "the methodology should be disclosed to the public, which could be one way to evaluate how 'scientific' it is and if it is scientific enough". In essence, if the startup's research is a black box, we need to have a white-box explanation of its internal workings. The credibility of the research lies not in the public availability of the data, but in the replicability and rigor of the underlying scientific process and methodology. This approach allows investors and founders to make alignment based on authentic and accountable scientific findings.
10
-
Mehdi Maghsoodnia
1health.io • 7K followers
Exciting advancements in gene editing, spearheaded by UC Berkeley's Jennifer Doudna and her pioneering CRISPR research, are transforming the landscape. The CRISPR-based gene editing market is projected to reach approximately $4.5 billion in 2025, marking a remarkable 30% year-over-year increase. Forecasts indicate a substantial growth potential, with estimates soaring to $13-16 billion by 2034 at a consistent 25-30% compound annual growth rate. Globally, over 332 companies, with 217 based in the US, are driving innovation in 23 countries. Clinical trials, numbering around 250, with over 150 currently active, are focusing on diverse areas from blood disorders to rare diseases, showcasing impressive success rates ranging from 50-90% in experimental settings. Key developments in 2025, building upon Doudna's foundational work at Cal, include the introduction of personalized CRISPR infusions for treating rare childhood disorders, enhanced editing tools to minimize off-target effects, and RNA delivery techniques for repairing neurons in ALS cases. Biotechnology leads the adoption curve at approximately 40%, with academia and pharmaceutical sectors following suit. #CalGeneEditing #CRISPR #UCBerkeley #LifelongLearning
12
-
David H. Crean, Ph.D.
Cardiff Advisory LLC • 32K followers
I was honored to contribute insights to this piece on San Diego's biotech ecosystem—a market I've watched evolve significantly over 27 years in healthcare and life sciences. The article features 11 powerhouse companies, from Illumina and Thermo Fisher to emerging leaders like Element Biosciences and Crinetics. But beyond the profiles, it captures something essential about what makes San Diego different. Three observations from the ground: 1. Density without bureaucracy. The Mesa creates a true innovation corridor—UC San Diego, Salk, Scripps Research, and Sanford Burnham Prebys interweave with startups and scaled biopharma. This proximity reduces friction for diligence, talent recruitment, and specialized services in ways Boston and the Bay Area can't replicate. 2. Science-led, but transaction-optimized. San Diego has evolved from "discovery-first" to a complete company-building engine. Teams now design programs around pivotal endpoints, clean CMC plans, and partner-ready data packages earlier. Good science doesn't just get published here—it gets built. 3. Capital is increasingly earned. We're seeing more structured financing (tranched rounds, milestone-based pay-ins), CVRs, and hybrid collaborations. Strategic partners underwrite risk more explicitly. The winning teams treat capital strategy as a product—staging proof points and designing deal structures that preserve upside while de-risking 12-24 months out. Looking ahead, I expect San Diego's next growth phase to be defined by modality-driven oncology, neuroscience/neurodegeneration, precision immunology, and industrial-strength enabling platforms. The market increasingly rewards companies that combine compelling biology, manufacturability, and a partner-ready clinical narrative. I hope you find the article worth a read, especially if you're tracking West Coast biotech or thinking about where innovation capital flows most efficiently. #Biotech #LifeSciences #SanDiego #Innovation #InvestmentBanking #Dealmaking #Healthcare
96
4 Comments -
Clay Fisher
Spark Capital • 2K followers
Much of the money and time in healthcare happens past the point of diagnosis. The money: $200B of spend on specialty drugs. The time: putting patients on therapies requires clinical judgment, and navigating a labyrinth of paperwork and people. The result is a byzantine status quo where patients get life saving therapies denied or delayed, and hospital systems capture only $80B of the $200B of drug spend that they originate. Latent’s groundbreaking clinical AI is a portal into the future. Patients get therapies quickly with personalized care, and hospitals transform their bottom line. As a result, Latent has seen extraordinary traction, working with over 50% of the top 20 U.S. health systems in under a year. Latent is one of the biggest and most strategic opportunities in healthcare, sitting in between providers, payors, patients, and pharma. Spark Capital is delighted to support Rishabh Jain and Sriram Somasundaram and this consequential company and to work with Sarah Guo and Michael Dixon.
68
-
Robin Lauber
Prediction Capital • 5K followers
Interesting developments lately around two companies in infinitas capital's and Korify Capital's portfolio, highlighting the renewed momentum in CNS and mental health therapeutics. Alto Neuroscience today announced a $120M private placement financing, providing significant capital to advance its precision psychiatry pipeline, which aims to match patients with treatments using biomarker-driven approaches. At the same time, Bloomberg (link in comments) reported that ATAI Life Sciences AG (ataiBeckley) is exploring strategic options for its lead psychedelic program BPL-003, including a potential partnership or sale that could value the asset at $2B+ as it moves into Phase 3 trials for treatment-resistant depression. Taken together, this reinforces two broader trends we are seeing in the market: 🧠 CNS is moving back to the top of pharma’s strategic agenda, particularly with a significant patent cliff approaching later this decade 💊 Psychedelic therapies are increasingly attracting interest from large pharmaceutical companies, as the clinical data continues to improve and regulatory pathways become clearer With enormous unmet need in mental health and multiple innovative approaches now reaching later clinical stages, neuroscience could become one of the most active biotech sectors in this cycle. #Biotech #Neuroscience #CNS #Psychedelics #BiotechInvesting
44
6 Comments -
Ryosuke Kimura
Japan Venture Capital… • 10K followers
Lila Sciences has raised $235M in its first financing round backed by Flagship Pioneering. Their mission? To create a fully autonomous science engine that generates hypotheses, runs experiments, and learns — all without human intervention. While many biotech moonshots focus on verticals like drug discovery, Lila's ambition stretches across biology: from therapeutics to materials science, agriculture, and energy. A true multi-domain bet on what AI + automation could unlock for human progress. It’s an exciting time for founders rethinking the scientific method itself. Curious to see what founders and investors in Japan will build next in this direction. Read more: https://lnkd.in/gzt_yyGE #DeepTech #Biotech #AIinScience #AutonomousResearch #FlagshipPioneering #LilaSciences #VentureCapital #StartupFunding
16
1 Comment -
Adam Hargreaves
CDC Global Solutions • 27K followers
Synthesize Bio have launched with a $10M seed round led by Madrona, with support from Sahsen Ventures, LLC, Inner Loop Capital, Point Field Partners, and AI2 Incubator. The Seattle-based startup is building biological foundation models with generative AI to accelerate drug discovery. 🤖 𝐓𝐡𝐞𝐢𝐫 𝐦𝐨𝐝𝐞𝐥𝐬 𝐚𝐢𝐦 𝐭𝐨: - Streamline the identification of high-confidence drug targets. - Simulate therapeutic responses. - Optimize clinical trial design. 🙌 Congratulations to Robert Bradley and the team and make sure you follow their journey with growth almost certain to follow. #AI #Bioinformatics #DrugDiscovery
5
-
Parul Singh
Massachusetts Institute of… • 16K followers
🧬 Programmable Biology is coming! 🧬 “I saw extraordinary software and hardware built to support Mechanical and Electrical engineers, but not Biologists. We were being sold equipment that costs 10x what it should, and performed 1/10th of what we needed.” — Roya Amini-Naieni, co-founder & CEO of Trilobio That’s the gap Trilobio is closing—and why programmable biology is finally getting the tooling it deserves. Trilobio isn’t just automating labs. It’s rethinking how biology gets done. Robotic workcells that run experiments end-to-end. Software that scientists (not just programmers) can actually use. And a platform that helps the same team run 10x more experiments, without burnout. This is the future of synthetic biology—and it’s being built by Roya and Max. If you care about the future of biotech, bookmark Trilobio. 🚀 Read more: https://lnkd.in/gNJvxevJ
12
1 Comment -
Ken Nelson
Echo IQ • 16K followers
HeartBeam’s Deep Learning Algorithms Demonstrate High Rates of Accuracy for Detecting Arrhythmias 1) New study presented at HRX Live 2025 demonstrates continued advancement of company’s AI program 2). HeartBeam's AI algorithm performed equally well on HeartBeam 3D ECG system and standard 12L ECGs in classifying atrial fibrillation, atrial flutter and sinus rhythm 3) Deep learning algorithms to be used for future FDA submissions to enhance product offerings HeartBeam Inc. (NASDAQ: BEAT) Heart Rhythm Society American Heart Association
23
-
Austin Walters
SpringTide Ventures • 13K followers
Proud of my friends Jared Conley, MD, PhD and Mike Senter-Zapata, MD and the entire team behind this important study with Mass General Brigham and Avo. This work meaningfully advances how we think about reducing cognitive burden for clinicians in emergent situations through true digital co-pilot approaches. Emergent care is fundamentally a cognitive challenge. The difficulty goes beyond the medicine itself. It’s the mental bandwidth required to track a deteriorating patient, keep the team aligned, and make the right call under real pressure. What Jared and colleagues explored is a question we should all be asking: How much better could rapid responses be if we systematically offloaded cognitive load to software that guides, clarifies, and standardizes in real time? Their study offers three core principles: 1. Lower cognitive load → higher clinical performance Physicians across training levels reported less stress, more structure, and higher perceived quality of care when using mobile, condition-specific pathways. This is the essence of a digital co-pilot: elevating the clinician’s judgment by reducing decision friction. 2. UX must match clinical experience One of the most insightful findings: PGY-2 residents rated navigation more difficult than senior attendings. The takeaway is clear — interfaces designed for experts can overwhelm novices. A true co-pilot must adapt to the operator’s cognitive state and experience level, especially when seconds matter. 3. Standardization makes care better These digital checklists, modeled after aviation safety, created a shared mental model across teams. In environments where fragmentation can cost lives, standardization becomes a force multiplier. This work goes far beyond rapid responses. It points to what the next generation of clinical support should look like. We’re already seeing parts of this take shape across the system: Avo — guiding clinicians through critical care in real time Bayesian Health — flagging deterioration early enough to change outcomes Aidin — cutting through the administrative fog that slows transfers Koda Health — removing uncertainty around a patient’s wishes before it reaches the bedside Different problems, different settings, but the same underlying idea: when you take cognitive burden off clinicians, the quality of care goes up. The term “co-pilot” only means something if the tool shows up the way clinicians do in tough moments — steady, useful, and out of the way. Jared and the team have produced an example of what that future can look like. Our healthcare system needs a lot more of this kind of work. https://lnkd.in/gWZ5PA5c?
67
3 Comments -
Nate Loewentheil
Commonweal Ventures • 13K followers
#AmTech Weekly Roundup: Ambience Healthcare raised $243 million in Series C funding from Oak HC/FT, Andreessen Horowitz, OpenAI, Kleiner Perkins, Optum Ventures, and Town Hall Ventures. Ambience is building AI documentation software to record patient appointments, generate comprehensive medical notes, and standardize coding/authorization workflows. Michael Ng, Nikhil Buduma Reveal Technology raised $30 million in Series B funding from Ballistic Ventures, Shield Capital, Booz Allen Hamilton, and others. Reveal’s two main offerings are 3D mappings generated from drone videos and mobile biometrics. They are deployed with the US Army, Special Operations Command, Marine Corps, and other NATO forces. Garrett Smith Prophet Security raised $30 million in Series A funding from Accel and Bain Capital Ventures. Prophet is applying agentic AI to Security Operations Centers (SOCs), or hubs for cybersecurity defenses within an organization. Kamal Shah, Vibhav Sreekanti #VC #HealthTech #Healthcare #Defense #Cybersecurity
43
3 Comments
Explore top content on LinkedIn
Find curated posts and insights for relevant topics all in one place.
View top contentOthers named Juan-Pablo Mas
-
Juan Pablo Mas
Buenos Aires -
Juan Pablo Mas
Argentina -
Juan Pablo Tornos Mas
Barcelona -
Juan Pablo Demonte Mas
Argentina
20 others named Juan-Pablo Mas are on LinkedIn
See others named Juan-Pablo Mas